blue cross blue shield glp 1 coverage 2025 MCT2D Alternatives to GLP-1 medication?

Adults and Youths Since 1999 WEDNESDAY, July 15, 2026 -- Obesity prevalence has risen substantially since 1999 and now affects more than 40 percent of U.S

Statements Author contributions IZ, MP, GA, FG, VC, AS, and FA participated in the study conceptualization

Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: From the STEP 9 randomised clinical trial

Metabolic Syndrome and Retatrutide : Metabolic syndrome is a cluster of conditions, including high blood pressure, high blood sugar, abnormal cholesterol levels, and excess abdominal fat, that significantly increase the risk of developing cardiovascular disease and type 2 diabetes

Highlights The starting tirzepatide dosage for weight management is low (2.5 mg weekly) and is increased slowly (by 2.5 mg weekly after at least 4 weeks) because side effects are common but usually temporary and manageable

Department of Health and Human Services, Silver Spring, pp 15